Weinbrenner C, Wang P, Downey J M
Department of Physiology, University of South Alabama, College of Medicine, Mobile 36688, USA.
Basic Res Cardiol. 1996 Sep-Oct;91(5):374-81. doi: 10.1007/BF00788717.
Depletion of glycogen has been proposed as the mechanism of protection from ischemic preconditioning. The hypothesis was tested by seeing whether pharmacological manipulation of preconditioning causes parallel changes in cardiac glycogen content. Five groups of isolated rabbit hearts were studied. Group 1 experienced 30 min of ischemia only. Group 2 (PC) was preconditioned with 5 min of global ischemia followed by 10 min of reperfusion. Group 3 was preconditioned with 5 min exposure to 400 nM bradykinin followed by a 10 min washout period. Group 4 experienced exposure to 10 microM adenosine followed by a 10 min washout period, and the fifth group was also preconditioned with 5 min ischemia and 10 min reperfusion but 100 microM 8-(p-sulfophenyl)theophylline (SPT), which blocks adenosine receptors, was included in the buffer to block preconditioning's protection. Transmural biopsies were taken before treatment, just prior to the 30 min period of global ischemia, and after 30 min of global ischemia. Glycogen in the samples was digested with amyloglucosidase and the resulting glucose was assayed. Baseline glycogen averaged 17.3 +/- 0.6 mumol glucose/g wet weight. After preconditioning glycogen decreased to 13.3 +/- 1.3 mumol glucose/g wet weight (p < 0.005 vs. baseline). Glycogen was similarly depleted after pharmacological preconditioning with adenosine (14.0 +/- 1.0 mumol glucose/g wet weight, p < 0.05 vs. baseline) suggesting a correlation. However, when preconditioning was performed in the presence of SPT, which blocks protection, glycogen was also depleted by the same amount (13.3 +/- 0.7 mumol glucose/g wet weight, p = ns vs. PC). Bradykinin, which also mimics preconditioning, caused no depletion of glycogen (16.3 +/- 0.8 mumol glucose/g wet weight, p = ns vs. baseline). Because preconditioning with bradykinin did not deplete glycogen and because glycogen continued to be low when protection from preconditioning was blocked with SPT, we conclude that loss of glycogen per se does not cause the protection of preconditioning.
糖原耗竭被认为是缺血预处理保护作用的机制。通过观察预处理的药理学操作是否会引起心脏糖原含量的平行变化来验证这一假说。研究了五组离体兔心脏。第1组仅经历30分钟的缺血。第2组(PC组)用5分钟的全心缺血预处理,随后再灌注10分钟。第3组用400 nM缓激肽处理5分钟,随后冲洗10分钟进行预处理。第4组用10 μM腺苷处理,随后冲洗10分钟,第五组也用5分钟缺血和10分钟再灌注预处理,但缓冲液中加入100 μM 8-(对磺基苯基)茶碱(SPT)以阻断腺苷受体,从而阻断预处理的保护作用。在处理前、全心缺血30分钟前以及全心缺血30分钟后进行透壁活检。样品中的糖原用淀粉葡萄糖苷酶消化,并测定产生的葡萄糖。基线糖原平均为17.3±0.6 μmol葡萄糖/克湿重。预处理后糖原降至13.3±1.3 μmol葡萄糖/克湿重(与基线相比,p<0.005)。用腺苷进行药理学预处理后糖原同样减少(14.0±1.0 μmol葡萄糖/克湿重,与基线相比,p<0.05),提示存在相关性。然而,当在SPT存在下进行预处理(阻断保护作用)时,糖原也减少了相同的量(13.3±0.7 μmol葡萄糖/克湿重,与PC组相比,p=无显著差异)。同样模拟预处理的缓激肽并未导致糖原减少(16.3±0.8 μmol葡萄糖/克湿重,与基线相比,p=无显著差异)。由于用缓激肽预处理并未使糖原减少,且当用SPT阻断预处理的保护作用时糖原持续处于低水平,我们得出结论,糖原本身的减少并不会导致预处理的保护作用。